Core Viewpoint - Gansu Province has introduced a policy plan to support the biopharmaceutical industry in the Lanzhou High-tech Zone, aiming to enhance innovation and promote sustainable development in the sector [1][2]. Group 1: Policy Implementation - The plan focuses on supporting the industrialization of gene and cell therapies, AI in pharmaceuticals, new vaccines, and precision diagnostics [2]. - A three-tiered collaborative approach will be adopted to address the needs of trial tasks and optimize work measures [2]. - The plan includes establishing a project list for innovative medical devices and providing a "green channel" for product registration and approval processes [2]. Group 2: Industry Goals - By the end of 2027, the total output value of the biopharmaceutical industry in Lanzhou High-tech Zone is expected to exceed 30 billion yuan [3]. - The plan aims to develop 3-5 generic drugs or biological products, 2-3 innovative drugs, and 3-5 new medical devices [3]. - The goal includes introducing over 20 high-level talents in the biopharmaceutical field and establishing more than 10 biopharmaceutical companies in the national base [3]. Group 3: Company Opportunities - Companies like Lanzhou Mingde Pharmaceutical Co. are positioned to benefit from the plan, focusing on the full industrial chain development of sheep placenta [3]. - The plan aligns with ongoing research projects in collaboration with local universities, enhancing the company's competitive edge in the biopharmaceutical market [3]. - Zhongnong Weite Biotechnology Co. is also leveraging the plan to develop new vaccines, targeting significant animal disease prevention needs [4].